<doctag><picture><loc_61><loc_30><loc_190><loc_47></picture>
<text><loc_226><loc_29><loc_443><loc_49>Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.</text>
<section_header_level_1><loc_22><loc_55><loc_428><loc_88>Structural Neuroimaging Markers of Dementia: Insights from ROC Curve Analysis</section_header_level_1>
<section_header_level_1><loc_22><loc_99><loc_76><loc_108>Sam Pepper</section_header_level_1>
<text><loc_29><loc_110><loc_186><loc_119>University of Kansas Medical Center</text>
<text><loc_22><loc_121><loc_88><loc_130>Setorwu Dzesu</text>
<text><loc_29><loc_132><loc_186><loc_141>University of Kansas Medical Center</text>
<text><loc_22><loc_144><loc_82><loc_153>Lauren Yoksh</text>
<text><loc_29><loc_155><loc_186><loc_164>University of Kansas Medical Center</text>
<text><loc_22><loc_167><loc_70><loc_176>Ankit Patel</text>
<text><loc_29><loc_179><loc_279><loc_188>University of Kansas, University of Kansas Medical Center</text>
<text><loc_22><loc_191><loc_81><loc_200>Robyn Honea</text>
<text><loc_29><loc_202><loc_279><loc_211>University of Kansas, University of Kansas Medical Center</text>
<text><loc_22><loc_214><loc_143><loc_223>Dinesh Pal Mudaranthakam</text>
<text><loc_29><loc_226><loc_156><loc_235>dmudaranthakam@kumc.edu</text>
<text><loc_29><loc_247><loc_186><loc_257>University of Kansas Medical Center</text>
<section_header_level_1><loc_22><loc_281><loc_94><loc_290>Research Article</section_header_level_1>
<text><loc_22><loc_300><loc_354><loc_310>Keywords: Neuroimaging, Dementia, Biomarkers, ROC Curves, Structural MRI</text>
<text><loc_22><loc_320><loc_97><loc_329>Posted Date:</text>
<text><loc_97><loc_320><loc_177><loc_329>September 17th, 2025</text>
<text><loc_22><loc_339><loc_237><loc_349>DOI: https://doi.org/10.21203/rs.3.rs-7418658/v1</text>
<text><loc_22><loc_359><loc_457><loc_378>License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License</text>
<text><loc_22><loc_388><loc_272><loc_397>Additional Declarations: No competing interests reported.</text>
<page_footer><loc_233><loc_485><loc_267><loc_491>Page 1/22</page_footer>
<page_break>
<section_header_level_1><loc_23><loc_21><loc_79><loc_36>Abstract</section_header_level_1>
<section_header_level_1><loc_23><loc_39><loc_114><loc_57>Background</section_header_level_1>
<text><loc_22><loc_64><loc_475><loc_131>Alzheimer's disease and related dementias (ADRD) are growing public health concerns. Early and accurate differentiation between cognitively normal (NL), mild cognitive impairment (MCI), and dementia is essential for timely intervention. Structural MRI biomarkers-such as grey matter volume (GMV), white matter volume (WMV), white matter hyperintensity volume (WMH), AD signature (a meta-region of interest), and hippocampal occupancy score (HOC)-offer promise for objectively staging cognitive decline.</text>
<section_header_level_1><loc_23><loc_147><loc_94><loc_164>Objective</section_header_level_1>
<text><loc_22><loc_171><loc_474><loc_204>This study aimed to evaluate the diagnostic utility of MRI-derived neuroimaging measures using receiver operating characteristic (ROC) curve analysis to identify optimal thresholds for distinguishing between NL, MCI, and dementia.</text>
<section_header_level_1><loc_23><loc_219><loc_91><loc_236>Methods</section_header_level_1>
<text><loc_22><loc_243><loc_475><loc_287>Data were collected from 466 participants at the KU Alzheimer's Disease Research Center between 2010 and 2025. T1-weighted MRI scans were preprocessed using SPM12 and VBM12. Statistical analyses included ANOVA, Tukey's HSD, Welch's t-tests, and ROC analyses. Youden's J statistic was used to determine optimal cut-points, and multivariate models assessed combined biomarker performance.</text>
<section_header_level_1><loc_23><loc_301><loc_80><loc_318>Results</section_header_level_1>
<text><loc_22><loc_325><loc_473><loc_404>Significant differences were found across diagnostic groups for GMV, WMH, AD signature, and HOC. ROC analysis for Demented vs the control group (NL) showed GMV had an AUC of 0.674 [0.6164, 0.7325], WMH an AUC of 0.700 [0.6454, 0.7539], AD signature an AUC of 0.829 [0.780, 0.8761], and HOC the highest individual performance with an AUC of 0.878 [0.8426, 0.9144]. Further ROC analysis confirmed AD signature and HOC as the most effective biomarkers (AUCs = 0.78 and 0.81) for distinguishing MCI/demented from NL. In MCI vs. Demented comparisons, AD signature and HOC biomarkers had AUCs of 0.70 and 0.73, respectively.</text>
<section_header_level_1><loc_23><loc_419><loc_117><loc_437>Conclusions</section_header_level_1>
<text><loc_22><loc_444><loc_470><loc_476>MRI-derived biomarkers, particularly AD signature and HOC, show strong potential for differentiating cognitive impairment stages. ROC-based thresholds offer clinically actionable metrics that can improve diagnostic precision.</text>
<page_footer><loc_233><loc_484><loc_267><loc_492>Page 2/22</page_footer>
<page_break>
<section_header_level_1><loc_23><loc_22><loc_102><loc_36>Introduction</section_header_level_1>
<text><loc_22><loc_43><loc_474><loc_109>Alzheimer's disease (AD) and related dementias (ARD) continue to pose significant public health challenges, with rising prevalence and limited therapeutic options. Accurate and early differentiation of disease stages-particularly between cognitively normal (NL), mild cognitive impairment (MCI), and dementia-is critical for prognosis, timely intervention, and appropriate patient management (Jack et al., 2010; Sperling et al., 2011). Neuroimaging has emerged as a powerful tool in this effort, offering noninvasive biomarkers that reflect structural and pathological brain changes associated with ADRD.</text>
<text><loc_22><loc_118><loc_475><loc_208>In particular, structural MRI has provided insight into alterations in grey matter density and volume, white matter volume (WMV), and white matter hyperintensities (WMH), each of which is implicated in neurodegenerative and cerebrovascular processes contributing to cognitive decline (Frisoni et al., 2010; Du et al., 2001; Debette & Markus, 2010). Grey matter atrophy has been consistently associated with Alzheimer's pathology, especially in the medial temporal lobe and neocortical regions (Fox et al., 20012007). Similarly, white matter degeneration and increased WMH burden are linked to small vessel disease and mixed dementia phenotypes, compounding the effects of primary neurodegeneration (Prins & Scheltens, 2015; Brickman et al., 2010).</text>
<text><loc_22><loc_218><loc_462><loc_295>Despite these advances, translating neuroimaging findings into clinically actionable tools remains a challenge. Current clinical practice often relies on qualitative interpretation or subjective thresholds, which may vary across institutions and practitioners (McEvoy & Brewer, 2010). By applying receiver operating characteristic (ROC) curve analyses to neuroimaging markers, we aim to derive optimal cutpoints that can discriminate between NL, MCI, and dementia with high sensitivity and specificity (Youden, W. J. 1950). These data-driven thresholds can support clinical teams in making objective assessments and tracking disease progression with greater precision.</text>
<text><loc_22><loc_305><loc_476><loc_461>The KU Alzheimer's Disease Center (KU ADC) offers a unique environment for investigating these relationships, featuring a well-characterized cohort, standardized imaging protocols, and structured diagnostic adjudication. Our work utilizes this rich dataset to evaluate the discriminative utility of MRIderived measures of grey matter, white matter, and WMH in distinguishing stages of cognitive impairment. These efforts align with broader national initiatives to develop quantitative imaging biomarkers that enhance clinical decision-making and personalized care in Alzheimer's disease-related dementia (ADRD) (Weiner et al., 2013; Hampel et al., 2021). The clinical utility of this approach is considerable. By providing threshold-based interpretations of neuroimaging findings, clinicians can more effectively distinguish between stages of cognitive impairment, particularly in diagnostically ambiguous cases. The longitudinal application of these metrics may aid in monitoring disease progression and identifying patients at high risk of converting to dementia. Moreover, standardized reporting of GMV, WMV, and WMH burden, tied to validated thresholds, can improve communication between radiologists, neurologists, primary care providers, and memory clinics. These findings also have implications for research infrastructure by enhancing recruitment strategies and precision in clinical trial design.</text>
<page_footer><loc_233><loc_484><loc_267><loc_491>Page 3/22</page_footer>
<page_break>
<text><loc_22><loc_22><loc_473><loc_68>In summary, our study bridges the gap between neuroimaging science and clinical utility by offering statistically significant MRI-derived structural markers in the context of ADRD. By operationalizing brain health indicators into clinically meaningful thresholds, this work advances the vision of a learning health system capable of proactive dementia care.</text>
<section_header_level_1><loc_23><loc_77><loc_81><loc_92>Methods</section_header_level_1>
<text><loc_22><loc_99><loc_309><loc_110>Standard Protocol Approvals, Registrations, and Patient Consents:</text>
<text><loc_22><loc_118><loc_464><loc_152>Study procedures were approved by the University of Kansas School of Medicine Institutional Review Board and were in accordance with U.S. federal regulations. All participants provided written informed consent.</text>
<text><loc_22><loc_160><loc_477><loc_307>Data Source: This analysis uses MRI brain scan data collected by the University of Kansas Alzheimer's Disease Research Center (KU ADRC) from 2010 to 2025. The KU ADRC is part of the U.S. network of Alzheimer's Disease Centers of Excellence that support research into brain aging and dementia. The KU ADRC has established an infrastructure for the identification, recruitment, and characterization of older adults both with and without dementia. Beginning in 2004, we developed a registry of individuals who have consented to be contacted regarding research studies, details of which have been published elsewhere (Vidoni et al., 2012). The KU ADRC obtains data on research participants as part of the National Alzheimer's Coordinating Center (NACC) requirements. These data are obtained by research and ethical standards. Individuals whose data are extracted give consent for the use of data for research and clinical purposes. Participants were recruited as part of intervention and observational studies at the University of Kansas Alzheimer's Disease Center (KU ADC) and were part of the Clinical Cohort. We have previously reported results from these investigations (Morris et al., 2017; Morris et al., 2020; Vidoni et al., 2015).</text>
<text><loc_22><loc_315><loc_475><loc_451>All participants also underwent a standard examination, which includes a thorough clinical and cognitive evaluation with a clinician at the KU ADC. This clinical evaluation includes a semi-structured interview (Clinical Dementia Rating, CDR) with the participant and study partner (Morris, 1993), as well as a physical and neurological examination. Clinical evaluation results were used to determine dementia status, which were reviewed along with psychometric battery results and finalized at a consensus diagnostic conference attended by clinicians and psychometricians using the NINCDS-ADRDA criteria as well as the McKann NIA-AA workgroup diagnostic guidelines (Beach et al., 2012; McKhann et al., 2011). Diagnostic criteria for AD require the gradual onset and progression of impairment in memory and in at least one other cognitive and functional domain on the CDR. MCI was diagnosed by a clinician and verified with medical records. Individuals were excluded from participating if they had other neurological disorders that could impair cognition, evidence of bleeding disorders during screening, clinically significant disease, psychiatric disorder, systemic illness, stroke, or myocardial infarction.</text>
<text><loc_22><loc_459><loc_471><loc_482>The following categories classified the cognition status of participants in the cohort; Mild Cognitive Impairment (MCI), Impaired, Demented (including AD) and the Control or healthy group (NL). Individuals</text>
<page_footer><loc_233><loc_485><loc_267><loc_492>Page 4/22</page_footer>
<page_break>
<text><loc_22><loc_24><loc_476><loc_78>who were cognitively unimpaired (CU) were included at age 60 and older, while individuals with a dementia diagnosis were included regardless of age. The Uniform Data Set (UDS) was created in 2005 to collect standard clinical data on participants from the National Institute on Aging (NIA)-supported Alzheimer's Disease Centers (ADCs). The UDS is administered to ADC Clinical Cohort participants on an approximately annual basis.</text>
<text><loc_22><loc_88><loc_468><loc_132>The data obtained include participant cognition status, demographic information and other health related indicators like systolic and diastolic blood pressure, heart rate, sleep apnea, BMI, cardiac arrest, arthritis, incontinence, seizures, diabetes status, insomnia, alcohol intake, ptsd, bipolar, anxiety, vision, hearing, hypertension, hypercholesterolemia etc.</text>
<text><loc_22><loc_142><loc_477><loc_400>Preprocessing of MRI Data: All participants coming through neuroimaging studies at the KUADC underwent magnetic resonance imaging (MRI) of the brain in either a Siemens 3.0 Tesla Allegra or Skyra scanner. We obtained a high resolution T1-weighted image (MP-RAGE; 1×1×1mm voxels; TR = 2500ms, TE = 4.38ms, TI = 1100, FOV = 256X256 with 18% oversample, 1mm slice thickness, flip angle 8deg) for detailed anatomy with high gray-white matter contrast. Every scan was checked for image artifacts and gross anatomical abnormalities. 466 individuals with MPRAGE scans passed quality control. For volumetric pre-processing of T1-weighted images, we used the Computational Anatomical Toolbox 12 (CAT12 Version 12.6, C. Gaser, Structural Brain Mapping Group, Jena University Hospital, Jena, Germany; http://dbm.neuro.uni-jena.de/cat/) through Statistical Parametric Mapping version 12 (SPM12; Wellcome Trust Centre for Neuroimaging, London, UK: http://www.fil.ion.ucl.ac.uk/spm/software/spm12/)) that operate under Matlab (R2023a) (the Mathworks, Natick, MA) on Mac. T1 images were corrected for biasfield inhomogeneities, registered using linear (12-parameter affine) and non-linear transformations, spatially normalized using the high-dimensional DARTEL algorithm into MNI space(Ashburner, 2007), and segmented into gray matter (GM), white matter (WM), cerebrospinal fluid (CSF) and white matter hyperintensity (WMH). We calculated total intracranial volume (TIV) using total gray, white, and CSF volumes. We chose to use two specific calculated imaging biomarkers that are sensitive to disease progression and AD genetic risk [30, 31]. We computed a hippocampal occupancy score (HOC) as an estimate of medial temporal lobe atrophy, by determining the ratio of left and right hippocampal volume to the sum of the hippocampal and interior lateral ventricular volumes. HOC has been shown to have a higher discriminative accuracy than the standard hippocampal volume measure [32]. We also calculated an AD Signature composite which included gray matter medial (hippocampus, parahippocampus, entorhinal cortices), middle and inferior and superior temporal cortex volumes (regions summarized in Fig. 1, hippocampus not shown) [33, 34].</text>
<text><loc_22><loc_411><loc_476><loc_477>Data Processing: Box plots visualizing the distribution of grey matter volume, white matter volume, white matter hyperintensities, AD signature, and hippocampal occupancy score (HOC) were constructed based on the four primary diagnosis categories and summary statistics were observed. Analysis of variance (ANOVA) tests were performed to test for differences in distribution between primary diagnosis groups for these five variables of interest. Tukey's Honest Significant Difference (HSD) tests were evaluated following the ANOVA tests to detect significant differences between specific primary diagnosis groups,</text>
<page_footer><loc_233><loc_485><loc_267><loc_492>Page 5/22</page_footer>
<page_break>
<text><loc_22><loc_23><loc_477><loc_56>and confidence intervals for specific group comparisons were constructed. Density plots were created to compare the densities of the distributions of the five variables of interest for primary diagnosis groups Demented, MCI, and NL.</text>
<text><loc_22><loc_65><loc_460><loc_97>Similar analyses were performed comparing only demented and NL primary diagnosis groups. Welch two-sample t-tests were performed to compare the means of the two groups for each of the five variables of interest.</text>
<text><loc_22><loc_106><loc_475><loc_231>ROC Curve: Using the collapsed version of the data set in which primary diagnosis has two values, Demented and NL. We also considered the scenarios of MCI vs the control group (NL). We further combined the MCI group with the Demented group against the control. ROC curves were constructed for grey matter, white matter, white matter hyperintensities, AD signature, and HOC. The ROC curves were produced using the roc function for each scenario. This data was then plotted to create the ROC curves, with sensitivity on the y-axis and 1-specificity on the x-axis. Youden's J statistics were calculated to determine the optimal cut-point for each ROC curve, and this point was added to the ROC curve plots (Youden, W. J. 1950). The area under the curve (AUC) together with 95% CIs were calculated for each ROC curve and reported on the plots. In the scenarios of MCI and Demented vs control, and MCI vs control, ROC curves were illustrated in a single plot for better visualization of biomarker performance. All analyses were performed using R version 4.5.0.</text>
<section_header_level_1><loc_23><loc_241><loc_72><loc_256>Results</section_header_level_1>
<text><loc_22><loc_264><loc_476><loc_318>The final cohort for this study includes a total of 466 participants. The primary diagnoses of the cohort include 128 dementia, 14 impaired, 74 mild cognitive impairment (MCI), and 250 cognitively normal (NL). No significant difference in age or race was found between MCI and demented groups, nor between NL and the combined MCI and demented groups. There was a significant difference in years of education between MCI and Demented groups as well as between NL and combined MCI and demented groups.</text>
<text><loc_22><loc_327><loc_54><loc_337>Table 1</text>
<page_footer><loc_233><loc_484><loc_267><loc_491>Page 6/22</page_footer>
<page_break>
<otsl><loc_24><loc_22><loc_476><loc_484><fcel>Variable/Biomarker<fcel>MCI & Demented (n = 202)<fcel>Control (n = 250)<fcel>P-value<fcel>MCI (n = 137)<fcel>Demented (n = 216)<fcel>P-value<nl><fcel>Age at Visit Mean(sd)<fcel>74.8<fcel>73.8<fcel>0.1638<fcel>73.9<fcel>75.2<fcel>0.2392<nl><fcel>Presumed Disease Status at Enrollment<ecel><ecel><fcel>< 0.0001<ecel><ecel><fcel>0.0346<ecel><nl><fcel>Case<fcel>38 (0.86)<fcel>6 (0.14)<ecel><fcel>7(0.18)<fcel>31(0.82)<ecel><nl><fcel>Control<fcel>8<fcel>42 (0.84)<ecel><fcel>3(0.38)<fcel>5(0.62)<ecel><nl><fcel>No Presumed Disease<fcel>156<fcel>202<ecel><fcel>64<fcel>92<ecel><nl><fcel>Sex<fcel>(0.44)<fcel>(0.56)<ecel><fcel>(0.41)<fcel>(0.59)<ecel><nl><fcel>Male<fcel>107<fcel>85 (0.44)<ecel><fcel>41(0.38)<fcel>66(0.62)<ecel><nl><fcel>Female<fcel>95<fcel>165 (0.63)<ecel><fcel>33(0.35)<fcel>62(0.65)<ecel><nl><fcel>Race<fcel>(0.37)<ecel><ecel><fcel>0.6792<ecel><fcel>0.7633<nl><fcel>White<fcel>185<fcel>230 (0.55)<ecel><fcel>67<fcel>118<ecel><nl><fcel>Black or African American<fcel>12<fcel>16 (0.57)<ecel><fcel>5 (0.42)<fcel>7 (0.58)<ecel><nl><fcel>American Indian or Alaska Native<fcel>0<fcel>1<ecel><fcel>0<fcel>0<ecel><nl><fcel>Asian<fcel>1<fcel>2<ecel><fcel>0 (0.00)<fcel>1 (1.00)<ecel><nl><fcel>Others<fcel>(0.33)<fcel>(0.67)<ecel><fcel>2 (0.50)<fcel>2 (0.50)<ecel><nl><fcel>Education (Number of years)<fcel>15.7<fcel>16.7<fcel>0.0003<fcel>16.1<fcel>15.5<fcel>0.1806<nl></otsl>
<page_footer><loc_233><loc_485><loc_267><loc_492>Page 7/22</page_footer>
<page_break>
<otsl><loc_22><loc_22><loc_477><loc_228></otsl>
<text><loc_22><loc_237><loc_449><loc_267>ANOVA tests found significant differences in the distributions of grey matter volume, white matter hyperintensities, AD signature, and HOC between the four primary diagnosis groups. Significant differences in grey matter were found between diagnosis groups impaired</text>
<text><loc_22><loc_277><loc_480><loc_333>versus demented, MCI versus demented, and NL versus demented. Welch's two-sample t-test for demented and NL diagnosis groups found a significant difference in grey matter distribution between the two groups (p</text>
<otsl><loc_22><loc_360><loc_477><loc_447><caption><loc_129><loc_341><loc_371><loc_359>Table 2 a: Four diagnosis group Grey Matter summary statistics</caption></otsl>
<page_footer><loc_233><loc_485><loc_267><loc_491>Page 8/22</page_footer>
<page_break>
<otsl><loc_22><loc_41><loc_478><loc_98><fcel>Cognition  Status<fcel>Count<fcel>Mean<fcel>Median<fcel>SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>561.76<fcel>562.60<fcel>55.95<fcel>70.86<fcel>528.31<fcel>599.16<fcel>399.57<fcel>686.09<nl><fcel>NL<fcel>250<fcel>596.35<fcel>595.93<fcel>50.93<fcel>69.49<fcel>559.17<fcel>628.66<fcel>456.95<fcel>776.86<nl><caption><loc_129><loc_23><loc_370><loc_43>Table 2 b: Two diagnosis group Grey Matter summary statistics</caption></otsl>
<text><loc_22><loc_106><loc_476><loc_161>Significant differences in white matter hyperintensities were found between diagnosis groups NL versus demented and NL versus impaired, and the two-sample t-test provided a significant result comparing demented versus NL groups (p</text>
<otsl><loc_22><loc_187><loc_478><loc_275><fcel>Cognition  Status<fcel>Count<fcel>Mean<fcel>Median<fcel>SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>9.1537<fcel>5.570<fcel>9.218<fcel>8.620<fcel>3.265<fcel>11.885<fcel>0.99<fcel>49.082<nl><fcel>Impaired<fcel>14<fcel>15.120<fcel>5.570<fcel>18.73<fcel>20.123<fcel>2.525<fcel>22.652<fcel>1.53<fcel>58.860<nl><fcel>MCI<fcel>74<fcel>7.003<fcel>3.445<fcel>8.228<fcel>4.523<fcel>2.153<fcel>6.675<fcel>0.58<fcel>35.345<nl><fcel>NL<fcel>250<fcel>5.134<fcel>2.960<fcel>6.595<fcel>4.070<fcel>1.880<fcel>5.950<fcel>0.50<fcel>62.420<nl><caption><loc_90><loc_169><loc_409><loc_189>Table 3 a: Four diagnosis group White Matter Hyperintensities summary statistics</caption></otsl>
<otsl><loc_22><loc_304><loc_478><loc_357><fcel>Cognition  Status<fcel>Count<fcel>Mean<fcel>Median<fcel>SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>9.1537<fcel>5.570<fcel>9.218<fcel>8.620<fcel>3.265<fcel>11.885<fcel>0.99<fcel>49.082<nl><fcel>NL<fcel>250<fcel>5.134<fcel>2.960<fcel>6.595<fcel>4.070<fcel>1.880<fcel>5.950<fcel>0.50<fcel>62.420<nl><caption><loc_90><loc_285><loc_409><loc_304>Table 3 b: Two diagnosis group White Matter Hyperintensities summary statistics</caption></otsl>
<text><loc_22><loc_365><loc_480><loc_432>Significant differences in AD signature were found between diagnosis groups impaired versus demented, MCI versus demented, MCI versus impaired, and NL versus MCI. The two-sample ttest comparing the collapsed two-diagnosis group data set found a significant difference in AD signature between demented and NL groups (p</text>
<page_footer><loc_233><loc_485><loc_267><loc_492>Page 9/22</page_footer>
<page_break>
<otsl><loc_22><loc_41><loc_477><loc_128><fcel>Cognition Status<fcel>Count Mean<fcel>Median SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>0.1056<fcel>0.1056<fcel>0.007<fcel>0.009<fcel>0.1019<fcel>0.1106<nl><fcel>Impaired<fcel>14<fcel>0.1121<fcel>0.1122<fcel>0.006<fcel>0.009<fcel>0.1080<fcel>0.1173<nl><fcel>MCI<fcel>74<fcel>0.1100<fcel>0.1102<fcel>0.005<fcel>0.006<fcel>0.1065<fcel>0.1130<nl><fcel>NL<fcel>250<fcel>0.1132<fcel>0.1130<fcel>0.004<fcel>0.006<fcel>0.1105<fcel>0.1162<nl><caption><loc_126><loc_23><loc_374><loc_42>Table 4 a: Four diagnosis group AD Signature summary statistics</caption></otsl>
<otsl><loc_22><loc_155><loc_477><loc_211><fcel>Cognition Status<fcel>Count Mean<fcel>Median SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>0.1056<fcel>0.1056<fcel>0.007<fcel>0.009<fcel>0.1019<fcel>0.1106<nl><fcel>NL<fcel>250<fcel>0.1132<fcel>0.1130<fcel>0.004<fcel>0.006<fcel>0.1105<fcel>0.1162<nl></otsl>
<text><loc_22><loc_219><loc_476><loc_273>Significant differences in HOC were found between diagnosis groups impaired versus demented, MCI versus demented, NL versus demented, and NL versus MCI. The two-sample t-test provided a significant result comparing demented versus NL groups (p</text>
<otsl><loc_23><loc_301><loc_476><loc_380><fcel>Cognition Status<fcel>Count Mean<fcel>Median SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>0.935<fcel>0.947<fcel>0.042<fcel>0.047<fcel>0.920<fcel>0.967<nl><fcel>Impaired<fcel>14<fcel>0.970<fcel>0.977<fcel>0.022<fcel>0.013<fcel>0.969<fcel>0.981<nl><fcel>MCI<fcel>74<fcel>0.961<fcel>0.970<fcel>0.028<fcel>0.027<fcel>0.952<fcel>0.979<nl><fcel>NL<fcel>250<fcel>0.976<fcel>0.979<fcel>0.015<fcel>0.013<fcel>0.971<fcel>0.985<nl><caption><loc_144><loc_283><loc_355><loc_302>Table 5 a: Four diagnosis group HOC summary statistics</caption></otsl>
<otsl><loc_23><loc_409><loc_476><loc_455><fcel>Cognition Status<fcel>Count Mean<fcel>Median SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>0.935<fcel>0.947<fcel>0.042<fcel>0.047<fcel>0.920<fcel>0.967<nl><fcel>NL<fcel>250<fcel>0.976<fcel>0.979<fcel>0.015<fcel>0.013<fcel>0.971<fcel>0.985<nl></otsl>
<page_footer><loc_231><loc_485><loc_269><loc_492>Page 10/22</page_footer>
<page_break>
<otsl><loc_22><loc_95><loc_477><loc_182><fcel>Primary  Diagnosis<fcel>Count<fcel>Mean<fcel>Median<fcel>SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>454.88<fcel>445.00<fcel>60.23<fcel>87.33<fcel>409.29<fcel>496.63<fcel>321.65<fcel>602.43<nl><fcel>Impaired<fcel>14<fcel>498.38<fcel>504.77<fcel>61.10<fcel>90.05<fcel>456.58<fcel>546.61<fcel>399.59<fcel>606.40<nl><fcel>MCI<fcel>74<fcel>471.23<fcel>468.47<fcel>58.55<fcel>72.72<fcel>435.45<fcel>508.17<fcel>348.77<fcel>589.40<nl><fcel>NL<fcel>250<fcel>468.18<fcel>464.96<fcel>59.16<fcel>79.03<fcel>428.55<fcel>507.58<fcel>312.58<fcel>637.87<nl><caption><loc_126><loc_76><loc_373><loc_95>Table 6 a: Four diagnosis group White Matter summary statistics</caption></otsl>
<otsl><loc_24><loc_206><loc_475><loc_256><fcel>Group<fcel>Count<fcel>Mean<fcel>Median<fcel>SD<fcel>IQR<fcel>Q1<fcel>Q3<fcel>Min<fcel>Max<nl><fcel>Demented<fcel>128<fcel>454.88<fcel>445.00<fcel>60.23<fcel>87.33<fcel>409.29<fcel>496.63<fcel>321.65<fcel>602.43<nl><fcel>NL<fcel>250<fcel>468.18<fcel>464.96<fcel>59.16<fcel>79.03<fcel>428.55<fcel>507.58<fcel>312.58<fcel>637.87<nl></otsl>
<text><loc_22><loc_265><loc_479><loc_386>The model comparing the combined diagnosis group MCI and demented with NL using all five predictor variables of interest provided similar results to the univariate models, with AD signature and HOC providing the largest AUC out of the five ROC curves (AUC = 0.78 and 0.81, respectively). The optimal thresholds for AD signature (0.1085) and HOC (0.9736) obtained from this model were nearly identical to those obtained from the univariate models. The resulting thresholds for grey matter volume, white matter volume, and white matter hyperintensities were 572.59, 409.55, and 2.42, respectively, which are similar to the thresholds reported from the univariate models. From this model, AD signature has the highest specificity at 0.8795, and white matter hyperintensities has the lowest specificity of 0.3815. White matter hyperintensities, however, has the highest sensitivity in this model, which was found to be 0.6884, and a corresponding specificity of 0.8366, and white matter volume has the lowest sensitivity of 0.2277. AD signature and HOC have the overall best operating characteristics in this model.</text>
<text><loc_22><loc_396><loc_475><loc_474>The model comparing MCI versus demented diagnosis groups as a function of all five variables did not provide as strong of results as the previous model. Once again, the ROC curves for AD signature and HOC provide the largest AUC, 0.70 and 0.73 respectively, and have similar thresholds to those found from previous models (0.1055 and 0.9607, respectively). In this model, white matter hyperintensity has the highest specificity of 0.7656, but the lowest corresponding sensitivity at 0.4865. This model resulted in a specificity of 0.5 and a sensitivity of 0.8649 for AD signature. HOC has a specificity of 0.6953 and sensitivity of 0.6622.</text>
<page_footer><loc_231><loc_484><loc_269><loc_491>Page 11/22</page_footer>
<page_break>
<otsl><loc_22><loc_35><loc_477><loc_159><fcel>Biomarker<fcel>MCI&Demented vs Control<lcel><lcel><fcel>MCI vs Demented<lcel><lcel><nl><ecel><fcel>Threshold<fcel>Specificity<fcel>Sensitivity<fcel>Threshold<fcel>Specificity<fcel>Sensitivity<nl><fcel>Gray Matter<fcel>572.59<fcel>0.6988<fcel>0.5248<fcel>587.545<fcel>0.6953<fcel>0.5405<nl><fcel>White Matter  Volume<fcel>409.455<fcel>0.8635<fcel>0.2277<fcel>442.265<fcel>0.4922<fcel>0.7027<nl><fcel>White Matter  Hyperintensities<fcel>2.42<fcel>0.3815<fcel>0.8366<fcel>3.17<fcel>0.7656<fcel>0.4865<nl><fcel>AD Signature<fcel>0.1085<fcel>0.8795<fcel>0.5792<fcel>0.1055<fcel>0.5<fcel>0.8649<nl><fcel>HOC<fcel>0.9736<fcel>0.7068<fcel>0.7871<fcel>0.9607<fcel>0.6953<fcel>0.6622<nl><caption><loc_234><loc_23><loc_266><loc_32>Table 7</caption></otsl>
<section_header_level_1><loc_23><loc_160><loc_95><loc_174>Discussion</section_header_level_1>
<text><loc_22><loc_180><loc_468><loc_270>This study demonstrates the potential of structural MRI-derived biomarkers-grey matter density, grey matter volume (GMV), white matter volume (WMV), and white matter hyperintensities (WMH)-to differentiate clinical stages of cognitive impairment along the Alzheimer's disease continuum. By applying ROC curve analysis to a rigorously phenotype cohort from the KU Alzheimer's Disease Center, we quantified the discriminative performance of these imaging features in distinguishing between normal cognition (NL), mild cognitive impairment (MCI), and dementia. Our results support the hypothesis that neuroimaging metrics can serve not only as correlates of cognitive status but also as diagnostic tools when linked to clinically relevant thresholds.</text>
<text><loc_22><loc_279><loc_479><loc_357>Among the imaging features assessed, grey matter volume and WMH burden showed strong classification performance, particularly in differentiating Demented from MCI and NL participants. This aligns with previous research demonstrating that cortical atrophy and cerebrovascular pathology are key hallmarks of Alzheimer's disease and related dementias (Jack et al., 2010; Brickman et al., 2012; Prins & Scheltens, 2015). The use of empirically derived thresholds via ROC optimization offers practical advancement: instead of relying solely on z-scores or percentiles, clinicians can now consider actionable cut-off points in imaging interpretation to support diagnostic clarity (Falahati et al., 2014).</text>
<text><loc_22><loc_366><loc_479><loc_455>One of the most notable contributions of this work is the generation of threshold values that may be translated into clinical workflows. For example, radiologists and neurologists could integrate these findings into structured reporting formats, highlighting when GMV or WMH burden exceeds thresholds predictive of MCI or dementia. This supports a more standardized and objective approach to neuroimaging interpretation, reducing variability and facilitating interdisciplinary decision-making (Weiner et al., 2017). Moreover, by incorporating these metrics into clinical dashboards or EHR-integrated decision support systems, longitudinal tracking of brain health can become more feasible within routine practice (Tosun et al., 2016).</text>
<page_footer><loc_231><loc_484><loc_269><loc_492>Page 12/22</page_footer>
<page_break>
<text><loc_22><loc_23><loc_475><loc_91>From a research infrastructure perspective, the integration of ROC-based thresholds enhances precision recruitment for clinical trials. Individuals who meet imaging criteria for early neurodegeneration may be prioritized for enrollment in prevention studies, thereby improving cohort enrichment strategies (Donohue et al., 2014). Similarly, these tools can aid in the stratification of participants in observational studies based on neuroimaging severity, leading to more robust subgroup analyses and outcome modeling (Dyrba et al., 2015).</text>
<text><loc_22><loc_100><loc_468><loc_189>However, this study is not without limitations. First, the diagnostic categories used as reference standards are based on clinical consensus, which may be subject to interrater variability (Albert et al., 2011). Second, while our sample reflects the characteristics of a tertiary Alzheimer's Disease Center, generalizability to more diverse or community-based populations remains to be tested (Morris et al., 2006). Future work should examine how these thresholds perform across different MRI acquisition protocols and scanner types to ensure broader applicability. Additionally, combining structural imaging with other modalities-such as functional MRI, PET imaging, or blood-based biomarkers-may enhance predictive accuracy and support multidimensional diagnostic models (Hampel et al., 2018).</text>
<text><loc_22><loc_198><loc_477><loc_264>In conclusion, this work represents a critical step toward operationalizing brain health metrics for clinical and translational purposes. By deriving and validating imaging thresholds for key neuroanatomical features, we move closer to a precision medicine approach to dementia care-one that supports early identification, individualized monitoring, and timely intervention. These findings lay the groundwork for future integration into digital health platforms, automated reporting tools, and adaptive learning systems, ultimately enhancing care for individuals across the Alzheimer's disease spectrum.</text>
<section_header_level_1><loc_23><loc_275><loc_105><loc_290>Declarations</section_header_level_1>
<section_header_level_1><loc_23><loc_297><loc_94><loc_308>Data Availability:</section_header_level_1>
<text><loc_22><loc_317><loc_465><loc_360>Detailed data cannot be shared publicly to protect the privacy of individual participants. Information to support the findings of these analyses is available by contacting the corresponding author, who, upon reasonable request and understanding of the intended use of the data, will provide the requested information in a manner that continues to protect individual patient information.</text>
<section_header_level_1><loc_23><loc_369><loc_61><loc_379>Funding:</section_header_level_1>
<text><loc_22><loc_388><loc_389><loc_398>This work was funded by grants from the National Institute on Aging P30 AG072973.</text>
<section_header_level_1><loc_23><loc_406><loc_106><loc_417>Conflict of Interest:</section_header_level_1>
<text><loc_22><loc_426><loc_452><loc_447>The authors (s) declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.</text>
<section_header_level_1><loc_22><loc_456><loc_101><loc_466>Acknowledgment:</section_header_level_1>
<page_footer><loc_231><loc_484><loc_269><loc_492>Page 13/22</page_footer>
<page_break>
<section_header_level_1><loc_23><loc_59><loc_173><loc_74>Author Contribution</section_header_level_1>
<text><loc_23><loc_83><loc_468><loc_115>SM, SD, AK have extracted the data using our data pipelines, SD and LY have worked on conducting the analysis. RH and DPM have overseen the project and have supervised SD. All the authors were involved with the initial manuscript draft, all authors have reviewed and approved the manuscript.</text>
<section_header_level_1><loc_23><loc_128><loc_97><loc_141>References</section_header_level_1>
<unordered_list><list_item><loc_31><loc_150><loc_440><loc_170>1. Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.</list_item>
<list_item><loc_31><loc_174><loc_473><loc_206>2. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups. Alzheimers Dement. 2011;7(3):280-292.</list_item>
<list_item><loc_31><loc_210><loc_422><loc_230>3. Frisoni GB, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67-77.</list_item>
<list_item><loc_31><loc_234><loc_475><loc_255>4. Du AT, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;71(4):441-447.</list_item>
<list_item><loc_31><loc_259><loc_464><loc_280>5. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ. 2010;341:c3666.</list_item>
<list_item><loc_31><loc_284><loc_453><loc_305>6. Fox NC, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. Brain. 1996;119(Pt 6):2001-2007.</list_item>
<list_item><loc_31><loc_309><loc_477><loc_330>7. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: An update. Nat Rev Neurol. 2015;11(3):157-165.</list_item>
<list_item><loc_31><loc_334><loc_462><loc_355>8. Brickman AM, et al. Cerebral autoregulation, white matter hyperintensities, and cognition in aging and dementia. Neurology. 2010;75(10):904-910.</list_item>
<list_item><loc_31><loc_359><loc_475><loc_380>9. McEvoy LK, Brewer JB. Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother. 2010;10(11):1675-1688.</list_item>
<list_item><loc_26><loc_384><loc_459><loc_404>10. Weiner MW, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111-e194.</list_item>
<list_item><loc_26><loc_408><loc_467><loc_429>11. Hampel H, et al. Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology toward the shift of clinical paradigms. Prog Neurobiol. 2021;198:101970.</list_item>
<list_item><loc_26><loc_433><loc_437><loc_454>12. Prins, N. D., & Scheltens, P. (2015). White matter hyperintensities, cognitive impairment, and dementia: An update. Nature Reviews Neurology, 11, 157-165.</list_item>
<list_item><loc_26><loc_458><loc_473><loc_479>13. Falahati, F., Westman, E., & Simmons, A. (2014). Multivariate data analysis and machine learning in Alzheimer's disease with a focus on structural magnetic resonance imaging. Journal of Alzheimer's</list_item>
</unordered_list>
<page_footer><loc_231><loc_485><loc_269><loc_492>Page 14/22</page_footer>
<page_break>
<text><loc_42><loc_24><loc_151><loc_33>Disease, 41(3), 685-708.</text>
<unordered_list><list_item><loc_26><loc_37><loc_451><loc_58>14. Weiner, M. W., et al. (2017). Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's & Dementia, 13(5), 547-556.</list_item>
<list_item><loc_26><loc_62><loc_446><loc_82>15. Tosun, D., et al. (2016). Tracking MRI markers of Alzheimer's Disease using machine learning. Journal of Alzheimer's Disease, 52(2), 569-582.</list_item>
<list_item><loc_26><loc_86><loc_432><loc_107>16. Donohue, M. C., et al. (2014). Estimating long-term cognitive decline from short-term data. Alzheimer's & Dementia, 10(5), S400-S410.</list_item>
<list_item><loc_26><loc_111><loc_432><loc_132>17. Dyrba, M., et al. (2015). Multimodal analysis of functional and structural disconnection in Alzheimer's disease using multiple kernel SVM. Human Brain Mapping, 36(6), 2118-2131.</list_item>
<list_item><loc_26><loc_136><loc_466><loc_168>18. Albert, M. S., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups. Alzheimer's & Dementia, 7(3), 270-279.</list_item>
<list_item><loc_26><loc_172><loc_475><loc_192>19. Morris, J. C., et al. (2006). Recruitment and retention of participants for Alzheimer disease research. Alzheimer Disease & Associated Disorders, 20(1), 19-27.</list_item>
<list_item><loc_26><loc_196><loc_464><loc_217>20. Hampel, H., et al. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639-652.</list_item>
<list_item><loc_26><loc_221><loc_364><loc_230>21. Youden, W. J. (1950). Index for rating diagnostic tests. Cancer, 3(1), 32-35.</list_item>
</unordered_list>
<section_header_level_1><loc_23><loc_242><loc_71><loc_256>Figures</section_header_level_1>
<page_footer><loc_231><loc_484><loc_269><loc_491>Page 15/22</page_footer>
<page_break>
<picture><loc_26><loc_27><loc_468><loc_283><caption><loc_23><loc_297><loc_58><loc_305>Figure 1</caption></picture>
<text><loc_23><loc_318><loc_105><loc_326>Analytical Data Set</text>
<page_footer><loc_231><loc_485><loc_269><loc_491>Page 16/22</page_footer>
<page_break>
<picture><loc_47><loc_59><loc_223><loc_149><caption><loc_48><loc_40><loc_85><loc_47>Figure 2a</caption></picture>
<picture><loc_47><loc_176><loc_231><loc_279><caption><loc_48><loc_172><loc_85><loc_178>Figure 2c</caption></picture>
<picture><loc_47><loc_192><loc_231><loc_279><caption><loc_23><loc_309><loc_58><loc_316>Figure 2</caption></picture>
<text><loc_23><loc_328><loc_184><loc_336>Legend not included with this version</text>
<page_footer><loc_231><loc_485><loc_269><loc_491>Page 17/22</page_footer>
<picture><loc_240><loc_76><loc_411><loc_146></picture>
<picture><loc_256><loc_187><loc_437><loc_280></picture>
<page_break>
<picture><loc_54><loc_66><loc_220><loc_152><caption><loc_67><loc_168><loc_103><loc_175>Figure 3c</caption></picture>
<picture><loc_56><loc_186><loc_228><loc_275><caption><loc_38><loc_307><loc_58><loc_315>Figure 3</caption></picture>
<text><loc_38><loc_327><loc_184><loc_335>Legend not included with this version</text>
<page_footer><loc_231><loc_486><loc_269><loc_492>Page 18/22</page_footer>
<picture><loc_248><loc_66><loc_433><loc_152></picture>
<picture><loc_247><loc_186><loc_425><loc_280></picture>
<page_break>
<picture><loc_63><loc_61><loc_228><loc_145><caption><loc_68><loc_43><loc_105><loc_51>Figure 4a</caption></picture>
<picture><loc_59><loc_179><loc_240><loc_273><caption><loc_68><loc_179><loc_189><loc_186>Figure 4c</caption></picture>
<section_header_level_1><loc_23><loc_306><loc_58><loc_315>Figure 4</section_header_level_1>
<text><loc_23><loc_327><loc_184><loc_335>Legend not included with this version</text>
<page_footer><loc_231><loc_485><loc_269><loc_491>Page 19/22</page_footer>
<picture><loc_253><loc_76><loc_424><loc_139><caption><loc_310><loc_57><loc_423><loc_65>95% family-wise confidence level</caption></picture>
<picture><loc_263><loc_180><loc_451><loc_279></picture>
<page_break>
<picture><loc_66><loc_64><loc_239><loc_152><caption><loc_332><loc_44><loc_368><loc_52>Figure 5b</caption></picture>
<picture><loc_80><loc_194><loc_241><loc_276><caption><loc_66><loc_172><loc_117><loc_179>Figure 5c</caption></picture>
<section_header_level_1><loc_23><loc_307><loc_58><loc_315>Figure 5</section_header_level_1>
<text><loc_23><loc_328><loc_184><loc_336>Legend not included with this version</text>
<page_footer><loc_231><loc_486><loc_269><loc_491>Page 20/22</page_footer>
<picture><loc_255><loc_82><loc_426><loc_146></picture>
<picture><loc_266><loc_194><loc_425><loc_277></picture>
<page_break>
<picture><loc_58><loc_64><loc_229><loc_148><caption><loc_319><loc_55><loc_422><loc_62>95% family-wise confidence level</caption></picture>
<picture><loc_58><loc_164><loc_229><loc_270><caption><loc_58><loc_164><loc_103><loc_171>Figure 6c</caption></picture>
<picture><loc_57><loc_181><loc_229><loc_270><caption><loc_58><loc_164><loc_103><loc_171>Figure 6c</caption></picture>
<picture><loc_241><loc_181><loc_429><loc_276><caption><loc_23><loc_307><loc_58><loc_315>Figure 6</caption></picture>
<text><loc_23><loc_327><loc_184><loc_335>Legend not included with this version</text>
<page_footer><loc_231><loc_485><loc_269><loc_491>Page 21/22</page_footer>
<page_break>
<picture><loc_52><loc_72><loc_233><loc_158><caption><loc_71><loc_42><loc_107><loc_49>Figure 7a</caption></picture>
<picture><loc_262><loc_72><loc_446><loc_158><caption><loc_23><loc_194><loc_58><loc_201>Figure 7</caption></picture>
<text><loc_23><loc_215><loc_184><loc_223>Legend not included with this version</text>
<page_footer><loc_231><loc_486><loc_269><loc_492>Page 22/22</page_footer>
</doctag>